Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | RUNX1 | Q01196 | 2/20 | 0.44 |
| ▸ | CBFB | Q13951 | 2/20 | 0.44 |
| ▸ | TRPM5 | Q9NZQ8 | 11/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | CLK1 | P49759 | 2/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.39 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL911755 | 0.83 | ESR2 (0.41) | GAAHTTALDH1A1MAPTHPGD | |
| SCHEMBL7378448 | 0.74 | TRPM5 (0.40) | TRPM5TRPA1 | |
| SCHEMBL1144862 | 0.74 | TRPM5 (0.43) | ALDH1A1MAPTTRPM5TRPA1 | |
| SCHEMBL8073725 | 0.74 | TRPM5 (0.46) | TRPM5TRPA1 | |
| SCHEMBL910814 | 0.74 | TRPM5 (0.40) | GAAHTTALDH1A1MAPTHPGD | |
| SCHEMBL27855062 | 0.74 | ESR1 (0.45) | TRPM5CLK1DYRK1ADYRK1BTRPA1 | |
| SCHEMBL26538140 | 0.71 | ESR1 (0.46) | ALDH1A1MAPTHPGDTRPM5DYRK1A | |
| SCHEMBL28850754 | 0.70 | NQO2 (0.34) | GAAHTTALDH1A1MAPTHPGD | |
| SCHEMBL23055253 | 0.69 | TRPM5 (0.50) | TRPM5TRPA1 | |
| SCHEMBL18171767 | 0.69 | TRPM5 (0.52) | TRPM5TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787430-B2 | Hemoglobin modifier compounds and uses thereof | FRONTHERA U.S. PHARMACEUTICALS LLC (US) | 2020-09-29 | — | — | US | disclosed |
| EP-3606921-A1 | NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA. | Inventiva (FR) | 2020-02-12 | — | — | EP | disclosed |
| US-20190330181-A1 | HEMOGLOBIN MODIFIER COMPOUNDS AND USES THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2019-10-31 | — | — | US | disclosed |
| WO-2018185266-A1 | NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA. | INVENTIVA (FR) | 2018-10-11 | — | — | WO | disclosed |
| WO-2017218960-A1 | HEMOGLOBIN MODIFIER COMPOUNDS AND USES THEREOF | FRONTHERA U.S. PHARMACEUTICALS LLC (US) | 2017-12-21 | — | — | WO | disclosed |
| US-7868017-B2 | 9-azabicyclo[3.3.1]nonane derivatives | N.V. ORGANON (NL) | 2011-01-11 | — | — | US | disclosed |
| US-7868017-B2 | 9-azabicyclo[3.3.1]nonane derivatives | N.V. ORGANON (NL) | 2011-01-11 | — | — | US | disclosed |
| US-7868017-B2 | 9-azabicyclo[3.3.1]nonane derivatives | N.V. ORGANON (NL) | 2011-01-11 | — | — | US | disclosed |
| EP-1934212-A1 | 9-AZABICYCLO [3 . 3 . 1]NONANE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS | N.V. Organon (NL) | 2008-06-25 | — | — | EP | disclosed |
| US-20070112019-A1 | 9-Azabicyclo[3.3.1]nonane derivatives | N.V. ORGANON (NL) | 2007-05-17 | — | — | US | disclosed |
| US-20070112019-A1 | 9-Azabicyclo[3.3.1]nonane derivatives | N.V. ORGANON (NL) | 2007-05-17 | — | — | US | disclosed |
| US-20070112019-A1 | 9-Azabicyclo[3.3.1]nonane derivatives | N.V. ORGANON (NL) | 2007-05-17 | — | — | US | disclosed |
| WO-2007039563-A1 | 9-AZABICYCLO [3 . 3 . 1] NONANE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS | N.V. ORGANON (NL) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039563-A1 | 9-AZABICYCLO [3 . 3 . 1] NONANE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS | N.V. ORGANON (NL) | 2007-04-12 | — | — | WO | disclosed |
| EP-0157360-B1 | CHROMOGENIC ESTERS OF AMINO ACIDS AND PEPTIDES, PROCESSES FOR THEIR PREPARATION, USE OF THESE AGENTS IN METHODS OF ANALYSIS AND AGENTS FOR DETECTION OF ESTEROLYTIC AND/OR PROTEOLYTIC ENZYMES | MILES INC. (US) | 1991-08-14 | — | — | EP | disclosed |
| US-4806423-A | Agents and process for the detection of esterolytic and/or proteolytic enzymes | MILES INC. (US) | 1989-02-21 | — | — | US | disclosed |
| US-4723020-A | Chromogenic amino acid esters and peptide esters | MILES LABORATORIES, INC. (US) | 1988-02-02 | — | — | US | disclosed |
| US-4589910-A | Novel 4'(benzisothiazo-5-yloxy)-phenylurea derivatives, their preparation and their use as herbicides | BASF AKTIENGESELLSCHAFT (DE) | 1986-05-20 | — | — | US | disclosed |
| EP-0157360-A2 | Chromogenic esters of amino acids and peptides, processes for their preparation, use of these agents in methods of analysis and agents for detection of esterolytic and/or proteolytic enzymes | MILES INC. (US) | 1985-10-09 | — | — | EP | disclosed |
| EP-0098972-A2 | 5-Phenoxybenzisothiazole-4'-urea derivatives, process for their preparation and their use as herbicides | BASF Aktiengesellschaft (DE) | 1984-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330181-A1 | HEMOGLOBIN MODIFIER COMPOUNDS AND USES THEREOF | HBB, HBG1, HBG2 | GAA 49/4885HTT 101/4885ALDH1A1 863/4885 |
| US-10787430-B2 | Hemoglobin modifier compounds and uses thereof | HBB, HBG1, HBG2 | GAA 49/4885HTT 101/4885ALDH1A1 863/4885 |
| US-20070112019-A1 | 9-Azabicyclo[3.3.1]nonane derivatives | AZI2, TPMT, TET3 | GAA 1453/4885HTT 2814/4885ALDH1A1 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.